A RWE assessment will take into account the evidence generated to date, along with an assessment of NHS or wider health care interest, and will broadly asses innovations on the following criteria:
• Unmet need assessed by relative priority nationally including assessment of potential health gain
• Affordability assessed by available resources and appropriate economic assessment (ROI)
• Feasibility assessed by likely ease of spread, including technical and operational elements.
If a product is not of sufficient priority or cannot be afforded, even if health benefits could be gained, there is little or no point in undertaking a RWE. To do so is one cause of pilot-itis. Other causes include undertaking an incomplete, poorly considered or poorly executed RWE.
There are already pockets of excellence in RWE across the AHSN Network – for example Oxford AHSN has a strength in cardiovascular disease, and a history of impactful RWE work in this space. Similarly in Yorkshire, with expertise in Point of Care diagnostics, we can see high value work impacting on spread and adoption at pace and scale.